Definitive Healthcare Corp. (NASDAQ:DH) Receives Consensus Recommendation of “Hold” from Brokerages

Shares of Definitive Healthcare Corp. (NASDAQ:DH) have received a consensus rating of “Hold” from the eleven ratings firms that are presently covering the firm, Marketbeat Ratings reports. Nine analysts have rated the stock with a hold recommendation and two have given a buy recommendation to the company. The average 12-month price objective among analysts that have issued ratings on the stock in the last year is $9.94.

Several equities analysts have recently issued reports on the stock. Canaccord Genuity Group dropped their price target on shares of Definitive Healthcare from $10.00 to $8.00 and set a “hold” rating for the company in a research note on Wednesday, May 8th. Needham & Company LLC reaffirmed a “hold” rating on shares of Definitive Healthcare in a research report on Wednesday, May 8th. Stifel Nicolaus reduced their price target on Definitive Healthcare from $11.00 to $9.50 and set a “buy” rating on the stock in a research report on Wednesday, May 8th. Morgan Stanley downgraded Definitive Healthcare from an “overweight” rating to an “equal weight” rating and lowered their price objective for the stock from $11.50 to $9.00 in a research report on Wednesday, May 8th. Finally, Deutsche Bank Aktiengesellschaft cut their price objective on Definitive Healthcare from $10.00 to $7.00 and set a “hold” rating on the stock in a research note on Thursday, May 9th.

Institutional Trading of Definitive Healthcare

Several hedge funds have recently modified their holdings of the stock. New York State Common Retirement Fund grew its stake in shares of Definitive Healthcare by 5.0% in the 3rd quarter. New York State Common Retirement Fund now owns 286,097 shares of the company’s stock valued at $2,286,000 after buying an additional 13,733 shares during the period. J.P. Morgan Private Wealth Advisors LLC acquired a new stake in Definitive Healthcare in the third quarter valued at approximately $131,000. Swiss National Bank increased its holdings in shares of Definitive Healthcare by 3.4% during the third quarter. Swiss National Bank now owns 96,900 shares of the company’s stock valued at $774,000 after acquiring an additional 3,200 shares in the last quarter. Envestnet Asset Management Inc. raised its position in shares of Definitive Healthcare by 41.7% during the third quarter. Envestnet Asset Management Inc. now owns 383,151 shares of the company’s stock worth $3,061,000 after purchasing an additional 112,718 shares during the period. Finally, WINTON GROUP Ltd acquired a new position in shares of Definitive Healthcare during the third quarter worth approximately $220,000. Institutional investors own 98.67% of the company’s stock.

Definitive Healthcare Trading Down 2.1 %

Shares of DH stock opened at $5.62 on Wednesday. The company has a quick ratio of 2.30, a current ratio of 2.30 and a debt-to-equity ratio of 0.20. The firm has a market capitalization of $662.77 million, a P/E ratio of -3.21, a P/E/G ratio of 4.07 and a beta of 1.29. Definitive Healthcare has a twelve month low of $4.38 and a twelve month high of $12.45. The stock’s fifty day simple moving average is $6.28 and its 200 day simple moving average is $7.97.

Definitive Healthcare (NASDAQ:DH) last released its quarterly earnings data on Tuesday, May 7th. The company reported ($0.02) earnings per share (EPS) for the quarter, missing the consensus estimate of $0.02 by ($0.04). Definitive Healthcare had a negative net margin of 78.16% and a positive return on equity of 0.51%. As a group, sell-side analysts predict that Definitive Healthcare will post 0.1 EPS for the current fiscal year.

Definitive Healthcare Company Profile

Definitive Healthcare Corp., together with its subsidiaries, provides software as a service (SaaS) healthcare commercial intelligence platform in the United States and internationally. Its SaaS platform provides information on healthcare providers and their activities to help its customers from product development to go-to-market planning, and sales and marketing execution.